Mesoblast Limited (MESO)

Market Cap	1.73B
Revenue (ttm)	5.90M
Net Income (ttm)	-87.96M
Shares Out	1.14B
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,924,956
Open	14.83
Previous Close	16.76
Day's Range	13.70 - 15.61
52-Week Range	1.61 - 19.15
Beta	2.34
Analysts	Strong Buy
Price Target	13.50 (-7.72%)
Earnings Date	Aug 28, 2024

About MESO

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn’s disease; and Remestemcel-L, whi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 73
• Stock Exchange: NASDAQ
• Ticker Symbol: MESO
• Website: https://www.mesoblast.com

Financial Performance

In 2024, Mesoblast's revenue was $5.90 million, a decrease of -21.32% compared to the previous year's $7.50 million. Losses were -$87.96 million, 7.41% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for MESO stock is "Strong Buy." The 12-month stock price forecast is $13.5, which is a decrease of -7.72% from the latest price.

Price Target

$13.5

(-7.72% downside)

Analyst Consensus: Strong Buy